Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Margaret von Mehren,John M. Kane,Mark Agulnik,Marilyn M. Bui,Janai Carr-Ascher,Edwin Choy,Mary Connelly,Sarah Dry,Kristen N. Ganjoo,Ricardo J. Gonzalez,Ashley M. Holder,Jade Homsi,Vicki L. Keedy,Ciara Marie Kelly,Edward S. Kim,David A. Liebner,Martin M McCarter,Sean V. McGarry,Nathan W. Mesko,Christian F. Meyer,Alberto S. Pappo,Amanda Parkes,Ivy A. Petersen,Seth M. Pollack,Matthew M. Poppe,Richard F. Riedel,Scott M. Schuetze,Jacob E. Shabason,Jason K. Sicklick,Matthew B. Spraker,Melissa Zimel,Lisa E Hang,Hema Sundar,Mary Anne Bergman +33 more
TLDR
This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.Abstract:
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.read more
Citations
More filters
Journal ArticleDOI
Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features
Fuqiang Wang,Jin-Tao Li,Pingxiang Li,Chao-Hui Zheng,Qi-Yue Chen,Chang-Ming Huang,Jian-Wei Xie +6 more
TL;DR: A nomogram constructed based on preoperative CT radiomics features could be used for RFS prediction in high/intermediate-risk GISTs and assist the clinical decision-making for GIST patients.
Journal ArticleDOI
Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges
TL;DR: In this article , a systematic review summarizes the current evidence for the use of CDK4/6 inhibitors in sarcoma while identifying molecular rationale and predictive biomarkers that provide the foundation for targeting the CDK 4/6 pathway.
Journal ArticleDOI
Recent Advances of Organ-on-a-Chip in Cancer Modeling Research
Xingxing Liu,Qiu-lan Su,Xiaoyu Zhang,Wen An Yang,Junhua Ning,Kangle Jia,Jinlan Xin,Huanling Li,Longfei Yu,Yuheng Liao,Diming Zhang +10 more
TL;DR: The organ-on-chip (OoC) platform, which integrates the technology of 3D cell culture, tissue engineering, and microfluidics, is emerging as a new method to simulate the critical structures of the in vivo tumor microenvironment and functional characteristics as discussed by the authors .
Journal ArticleDOI
Current treatment strategies and future perspectives for gastrointestinal stromal tumors
Yoichi Sugiyama,Masaru Sasaki,Mohei Kouyama,Tatsuya Tazaki,Shinya Takahashi,Atsushi Nakamitsu +5 more
TL;DR: The clinicopathological characteristics of GISTs are reviewed along with the minimally invasive and multidisciplinary treatment options available for these tumors and the future perspectives for diagnostic and treatment approaches forThese tumors have been discussed.
Journal ArticleDOI
Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas
Zhichao Tian,Weitao Yao +1 more
TL;DR: The efficacy of nab-paclitaxel against various non-sarcoma malignancies based on clinical trials with reported results is summarized and the similarities and differences among nab- paclitaxe, pac litaxel, and docetaxel are compared.
References
More filters
Journal ArticleDOI
Cancer statistics, 2022
TL;DR: Progress has stagnated for breast and prostate cancers but strengthened for lung cancer, coinciding with changes in medical practice related to cancer screening and/or treatment, and mortality patterns reflect incidence trends.
Journal ArticleDOI
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Alexander Drilon,Theodore W. Laetsch,Shivaani Kummar,Steven G. DuBois,Ulrik Lassen,George D. Demetri,Michael J. Nathenson,Robert C. Doebele,Anna F. Farago,Alberto S. Pappo,Brian Turpin,Afshin Dowlati,Marcia S. Brose,Leo Mascarenhas,Noah Federman,Jordan Berlin,Wafik S. El-Deiry,Christina S. Baik,John F. Deeken,Valentina Boni,Ramamoorthy Nagasubramanian,Matthew H. Taylor,Erin R. Rudzinski,Funda Meric-Bernstam,Davendra Sohal,Patrick C. Ma,Luis E. Raez,Jaclyn F. Hechtman,Ryma Benayed,Marc Ladanyi,Brian B. Tuch,Kevin Ebata,Scott Cruickshank,Nora Ku,Michael C. Cox,Douglas S. Hawkins,David S. Hong,David S. Hong,David M. Hyman +38 more
TL;DR: Larotrectinib had marked and durable antitumor activity in patients with TRK fusion–positive cancer, regardless of the age of the patient or of the tumor type.
Journal ArticleDOI
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf,Jean-Yves Blay,Sant P. Chawla,Dong Wan Kim,B. Bui-Nguyen,Paolo G. Casali,Patrick Schöffski,Massimo Aglietta,Arthur P. Staddon,Yasuo Beppu,Axel Le Cesne,Hans Gelderblom,Ian Judson,Nobuhito Araki,M. Ouali,Sandrine Marreaud,Rachel Hodge,Mohammed R. Dewji,Corneel Coens,George D. Demetri,Christopher D.M. Fletcher,Angelo Paolo Dei Tos,Peter Hohenberger +22 more
TL;DR: This phase 3 study investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.
Journal ArticleDOI
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Robert C. Doebele,Alexander Drilon,Alexander Drilon,Luis Paz-Ares,Salvatore Siena,Alice T. Shaw,Anna F. Farago,Collin M. Blakely,Takashi Seto,Byung Chul Cho,D. Tosi,Benjamin Besse,Sant P. Chawla,Lyudmila Bazhenova,John C. Krauss,Young Kwang Chae,Minal A. Barve,Ignacio Garrido-Laguna,Stephen V. Liu,Paul Conkling,Thomas John,Marwan Fakih,Darren Sigal,Herbert H. Loong,Gary L Buchschacher,Pilar Garrido,Jorge Nieva,Conor E. Steuer,Tobias Overbeck,Daniel W. Bowles,Elizabeth Fox,Todd Riehl,Edna Chow-Maneval,B. Simmons,Na Cui,Ann M. Johnson,Susan Eng,Timothy R. Wilson,George D. Demetri +38 more
TL;DR: Results show that entrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile.
Journal ArticleDOI
Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution.
TL;DR: In this study of patients with retroperitoneal STS, stage at presentation, high histologic grade, unresectable primary tumor, and positive gross margin are strongly associated with the tumor mortality rate.
Related Papers (5)
Soft tissue head and neck sarcoma: experience of a tertiary referral centre over a 15-year period.
L Harrison,T McCulloch,N Beasley +2 more